转移性激素敏感性前列腺癌的治疗:系统评价、网络Meta分析与获益-危害评估
该系统评价与网络Meta分析纳入截至2022年3月1日的10项随机对照试验,评估多西他赛、阿比特龙、恩扎卢胺、阿帕他胺、达罗他胺及放疗联合雄激素剥夺治疗(ADT)对转移性激素敏感性前列腺癌的生存、健康相关生活质量(HRQoL)与获益-危害平衡的影响。结果显示各全身联合方案均有生存获益,但均未显示明确的HRQoL改善;阿比特龙、恩扎卢胺、阿帕他胺联合ADT的净临床获益概率较高,含多西他赛方案较低。
要点
- 与单用ADT相比,ADT+多西他赛、ADT+阿比特龙、ADT+恩扎卢胺、ADT+阿帕他胺、ADT+多西他赛+达罗他胺均有生存获益,证据确定性自低至高不等。
- ADT+多西他赛短期HRQoL下降持续3-6个月;ADT+阿比特龙随访至24个月可能HRQoL获益;其余方案与单用ADT无差异。
- 所有全身联合治疗均增加3-5级不良事件发生率;阿比特龙、恩扎卢胺、阿帕他胺联合ADT净临床获益概率>60%,含多西他赛方案<40%。
核心结论
- 尽管各全身联合治疗均有显著生存获益,但与单用ADT相比均未显示明确的HRQoL改善。
- ADT+多西他赛存在短期HRQoL下降,ADT+阿比特龙、ADT+阿帕他胺、ADT+恩扎卢胺的净临床获益较高。
- 作者认为,在个体化决策并考虑经济因素的前提下,证据可能支持优先选择ADT联合雄激素受体轴靶向治疗而非含多西他赛策略。
研究设计与样本
- 系统评价、网络Meta分析与获益-危害评估,检索MEDLINE、EMBASE、CENTRAL和ClinicalTrials.gov至2022年3月1日。
- 纳入比较多西他赛、阿比特龙、恩扎卢胺、阿帕他胺、达罗他胺、放疗联合ADT相互之间或与单用ADT比较的随机对照试验(RCT),共10项RCT。
- 三名评价者独立双份进行筛选、数据提取和偏倚风险评估。
主要发现
- 与单用ADT相比,ADT+多西他赛(GRADE高确定性)、ADT+阿比特龙(中等确定性)、ADT+恩扎卢胺(低确定性)、ADT+阿帕他胺(高确定性)、ADT+多西他赛+达罗他胺(高确定性)均有相关生存获益。
- ADT+放疗仅在低体积新发mHSPC中显示有效。
- 与单用ADT相比,ADT+多西他赛短期HRQoL下降持续3-6个月(中等确定性),ADT+阿比特龙随访至24个月可能HRQoL获益(中等确定性)。
- ADT+恩扎卢胺、ADT+阿帕他胺或ADT+放疗与单用ADT相比HRQoL无差异(低至高确定性)。
- 所有全身联合治疗的3-5级不良事件发生率均增加;获益-危害评估显示ADT+阿比特龙、ADT+恩扎卢胺、ADT+阿帕他胺净临床获益概率>60%,ADT+多西他赛和ADT+多西他赛+达罗他胺净临床获益可能性<40%。
关键数值与推荐
- ADT+多西他赛 vs 单用ADT:生存获益,GRADE高确定性。
- ADT+阿比特龙 vs 单用ADT:生存获益,GRADE中等确定性;随访至24个月可能HRQoL获益,中等确定性。
- ADT+恩扎卢胺 vs 单用ADT:生存获益,GRADE低确定性;HRQoL无差异。
- ADT+阿帕他胺 vs 单用ADT:生存获益,GRADE高确定性;HRQoL无差异。
- ADT+多西他赛+达罗他胺 vs 单用ADT:生存获益,GRADE高确定性;净临床获益概率<40%。
临床怎么用
- 作者认为,证据可能支持优先选择ADT联合雄激素受体轴靶向治疗而非含多西他赛策略。
- 作者指出个体化决策仍然重要,且需考虑经济因素。
- 原文未据此给出其他推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Multiple treatments for metastatic, hormone-sensitive prostate cancer (mHSPC) are available, but their effects on health-related quality of life (HRQoL) and benefit-harm balance remain unclear. OBJECTIVE: To assess clinical effectiveness regarding survival and HRQoL, safety, and benefit-harm balance of mHSPC treatments. EVIDENCE ACQUISITION: We searched MEDLINE, EMBASE, CENTRAL, and ClinicalTrials.gov until March 1, 2022. Randomized controlled trials (RCTs) comparing docetaxel, abiraterone, enzalutamide, apalutamide, darolutamide, and radiotherapy combined with androgen deprivation therapy (ADT) mutually or with ADT alone were eligible. Three reviewers independently performed screening, data extraction, and risk of bias assessment in duplicate. EVIDENCE SYNTHESIS: Across ten RCTs, we found relevant survival benefits for ADT + docetaxel (high certainty according to the Grading of Recommendations, Assessment, Development and Evaluation [GRADE]), ADT + abiraterone (moderate certainty), ADT + enzalutamide (low certainty), ADT + apalutamide (high certainty), and ADT + docetaxel + darolutamide (high certainty) compared with ADT alone. ADT + radiotherapy appeared effective only in low-volume de novo mHSPC. We found a short-term HRQoL decrease lasting 3-6 mo for ADT + docetaxel (moderate certainty) and a potential HRQoL benefit for ADT + abiraterone up to 24 mo of follow-up (moderate certainty) compared with ADT alone. There was no difference in HRQoL for ADT + enzalutamide, ADT + apalutamide, or ADT + radiotherapy over ADT alone (low-high certainty). Grade 3-5 adverse effect rates were increased with all systemic combination treatments. A benefit-harm assessment showed high probabilities (>60%) for a net clinical benefit with ADT + abiraterone, ADT + enzalutamide, and ADT + apalutamide, while ADT + docetaxel and ADT + docetaxel + darolutamide appeared unlikely (<40%) to be beneficial. CONCLUSIONS: Despite substantial survival benefits, no systemic combination treatment showed a clear HRQoL improvement compared with ADT alone. We found evidence for a short-term HRQoL decline with ADT + docetaxel and a higher net clinical benefit with ADT + abiraterone, ADT + apalutamide and ADT + enzalutamide. While individualized decision-making remains important and economic factors need to be considered, the evidence may support a general preference for the combination of ADT with androgen receptor axis-targeted therapies over docetaxel-containing strategies. PATIENT SUMMARY: We assessed different combination treatments for metastatic hormone-sensitive prostate cancer. While survival was better with all systemic combination treatments, there was no clear improvement in health-related quality of life compared with androgen deprivation therapy alone. Novel hormonal combination treatments had a more favorable benefit-harm balance than combination treatments that include chemotherapy.
引用
- Menges D, Yebyo HG, Sivec-Muniz S, et al. Treatments for Metastatic Hormone-sensitive Prostate Cancer: Systematic Review, Network Meta-analysis, and Benefit-harm assessment. Eur Urol Oncol. 2022. PMID: 35599144. doi:10.1016/j.euo.2022.04.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。